AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28903959 — intervention group
Group type: COMPARATOR
Intervention: High-carbohydrate and high-fat breakfasts
Number of subjects: 20
Study 26779697 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 1% 1 mL subcutaneously
Number of subjects: 41
Study 26779697 — intervention group
Group type: COMPARATOR
Intervention: No local anesthesia (Control)
Number of subjects: 41
Study 26779697 — intervention group
Group type: EXPERIMENTAL
Intervention: Other systemically acting analgesia
Number of subjects: 41
Study 26779697 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard 22-gauge needle
Number of subjects: 41
Study 26779697 — intervention group
Group type: EXPERIMENTAL
Intervention: Smaller 25-gauge needle
Number of subjects: 41
Study 21946541 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning dosing of travoprost eye drops
Number of subjects: 30
Study 21946541 — intervention group
Group type: COMPARATOR
Intervention: Evening dosing of travoprost eye drops
Number of subjects: 30
Study 21946541 — intervention group
Group type: EXPERIMENTAL
Intervention: First month dosing of travoprost eye drops
Number of subjects: 30
Study 21946541 — intervention group
Group type: EXPERIMENTAL
Intervention: Second month dosing of travoprost eye drops
Number of subjects: 30
Study 21946541 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning dosing
Number of subjects: 30
Study 21946541 — intervention group
Group type: COMPARATOR
Intervention: Evening dosing
Number of subjects: 30
Study 21946541 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning dosing vs Evening dosing
Number of subjects: 30
Study 21252252 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet (15 En% protein, 30 En% carbohydrates, 55 En% fat)
Number of subjects: 20
Study 21252252 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet (15% energy as protein, 65 En% as carbohydrates, 20 En% as fat)
Number of subjects: 20
Study 21252252 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet
Number of subjects: 20
Study 21252252 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 20
Study 19148042 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone (3 doses before incision, 8 hours, and 16 hours later)
Number of subjects: 66
Study 19148042 — intervention group
Group type: COMPARATOR
Intervention: Saline (3 doses before incision, 8 hours, and 16 hours later)
Number of subjects: 66
Study 19148042 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups pooled for risk factor analysis
Number of subjects: 66
Study 18261348 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovenous laser therapy (EVLT)
Number of subjects: 80
Study 18261348 — intervention group
Group type: COMPARATOR
Intervention: Saphenous veins stripping
Number of subjects: 80
Study 18261348 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (EVLT and stripping)
Number of subjects: 80
Study 14695867 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose Insulin intervention (maintaining euglycaemia)
Number of subjects: 142
Study 14695867 — intervention group
Group type: EXPERIMENTAL
Intervention: Admission plasma glucose > or = 6.1 mmol/l and glycosylated haemoglobin > or = 6.2%
Number of subjects: 142
Study 14695867 — intervention group
Group type: COMPARATOR
Intervention: Total series of acute stroke admissions
Number of subjects: 142
Study 11402381 — intervention group
Group type: EXPERIMENTAL
Intervention: lotrafilcon A silicone hydrogel lenses (HDk; Dk = 140)
Number of subjects: 20
Study 11402381 — intervention group
Group type: EXPERIMENTAL
Intervention: etafilcon A hydrogel lenses (LDk; Dk = 18)
Number of subjects: 20
Study 11402381 — intervention group
Group type: COMPARATOR
Intervention: Control eyes (non-lens wearing)
Number of subjects: 20
Study 9605801 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen for 1 year
Number of subjects: 30000
Study 9605801 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen for 2 years
Number of subjects: 30000
Study 9605801 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen for about 5 years
Number of subjects: 30000
Study 9605801 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen for about 5 years (node-positive)
Number of subjects: 30000
Study 9605801 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen for about 5 years (node-negative)
Number of subjects: 30000
Study 7809567 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light (about 5,000 lux) for 6 hours on the first 2 night shifts
Number of subjects: 50
Study 7809567 — intervention group
Group type: EXPERIMENTAL
Intervention: Dark goggles during daylight
Number of subjects: 50
Study 7809567 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of bright light plus goggles
Number of subjects: 50
Study 7809567 — intervention group
Group type: COMPARATOR
Intervention: Dim light (< 500 lux) and no goggles
Number of subjects: 50
Study 7809567 — intervention group
Group type: COMPARATOR
Intervention: No goggles
Number of subjects: 50
Study 7809567 — intervention group
Group type: EXPERIMENTAL
Intervention: Goggles
Number of subjects: 50
Study 7809567 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger temperature-rhythm phase shifts
Number of subjects: 50
Study 3187466 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous ultrasound treatment
Number of subjects: 99
Study 3187466 — intervention group
Group type: COMPARATOR
Intervention: Placebo ultrasound treatment
Number of subjects: 99
Study 3187466 — intervention group
Group type: COMPARATOR
Intervention: Rest
Number of subjects: 99
Study 4140267 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid supplementation
Number of subjects: 20
Study 4140267 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 20
Study 31165217 — intervention group
Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 106
Study 31165217 — intervention group
Group type: EXPERIMENTAL
Intervention: Women and Men
Number of subjects: 106
Study 29808377 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosaprepitant (150 mg intravenous single dose)
Number of subjects: 1000
Study 29808377 — intervention group
Group type: COMPARATOR
Intervention: Control regimen (dexamethasone and ondansetron on day 1, ondansetron continuing through day 3)
Number of subjects: 1000
Study 27976447 — intervention group
Group type: COMPARATOR
Intervention: Sleep restriction (4 hours)
Number of subjects: 42
Study 27976447 — intervention group
Group type: EXPERIMENTAL
Intervention: Idealized sleep (9.5 hours)
Number of subjects: 42
Study 27976447 — intervention group
Group type: EXPERIMENTAL
Intervention: Both conditions
Number of subjects: 42
Study 26176994 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 56 μg/kg
Number of subjects: 84
Study 26176994 — intervention group
Group type: COMPARATOR
Intervention: Alfentanil doses (0, 10, 20, 30, 40, 50, 60 μg/kg)
Number of subjects: 84
Study 26176994 — intervention group
Group type: COMPARATOR
Intervention: Thiopental 4 mg/kg and Rocuronium 0.6 mg/kg
Number of subjects: 84
Study 23357440 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT), 16 sessions of weekly therapy
Number of subjects: 45
Study 23357440 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 45
Study 21458867 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane (4%-6% concentration, 0.7-0.9 MAC)
Number of subjects: 40
Study 21458867 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane (2%-2.5% concentration, 0.7-0.9 MAC)
Number of subjects: 40
Study 18678571 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy-led group exercise and staff continence and mobility facilitation training
Number of subjects: 34
Study 18678571 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 34
Study 16413556 — intervention group
Group type: EXPERIMENTAL
Intervention: Dunaliella capsules providing 60 mg beta-carotene/day (first trial)
Number of subjects: 42
Study 16413556 — intervention group
Group type: EXPERIMENTAL
Intervention: Dunaliella capsules (second trial)
Number of subjects: 42
Study 16413556 — intervention group
Group type: EXPERIMENTAL
Intervention: Dunaliella capsules (in mice)
Number of subjects: 42
Study 16413556 — intervention group
Group type: COMPARATOR
Intervention: Beta-carotene-deficient Dunaliella capsules (second trial)
Number of subjects: 42
Study 12883126 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil treatment taken as required before sexual activity, up to two times per week
Number of subjects: 65
Study 12883126 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil treatment
Number of subjects: 65
Study 12883126 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in sexual self-confidence and partner's wish to continue treatment
Number of subjects: 65
Study 12883126 — intervention group
Group type: EXPERIMENTAL
Intervention: High pretreatment sexual desire
Number of subjects: 65
Study 11052587 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg transdermal nicotine patches
Number of subjects: 5
Study 11052587 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 9206221 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification with small incision (6 mm) intraocular lens implantation
Number of subjects: 40
Study 1418072 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine (75 mg/d)
Number of subjects: 251
Study 1418072 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251
Study 1418072 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine (greater than 75 mg/d)
Number of subjects: 251
Study 10269521 — intervention group
Group type: EXPERIMENTAL
Intervention: Group counseling (experimental group 1) with 17 patients and their spouses
Number of subjects: 58
Study 10269521 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients participating in group counseling (experimental group 2) with 22 patients and their spouses
Number of subjects: 58
Study 10269521 — intervention group
Group type: COMPARATOR
Intervention: Control group with 19 patients and their spouses who did not participate in the experimental program
Number of subjects: 58
Study 29504820 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-step reduction (TSR) therapy of integrated Chinese and Western Medicine
Number of subjects: 60
Study 29504820 — intervention group
Group type: COMPARATOR
Intervention: Posterior open (PO) surgery
Number of subjects: 60
Study 29374717 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy (nCRT)
Number of subjects: 41
Study 29374717 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 41
Study 26758532 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of antihypertensive medication
Number of subjects: 162
Study 26758532 — intervention group
Group type: COMPARATOR
Intervention: Continuation of antihypertensive medication
Number of subjects: 162
Study 26758532 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete discontinuation of all antihypertensive medication
Number of subjects: 162
Study 25291923 — intervention group
Group type: EXPERIMENTAL
Intervention: Dedicated Education Units (DEUs)
Number of subjects: 34
Study 21897344 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxiplex gel (treatment group)
Number of subjects: 352
Study 19639351 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching to another statin
Number of subjects: 5800000
Study 19639351 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching more than once
Number of subjects: 5800000
Study 19639351 — intervention group
Group type: COMPARATOR
Intervention: Non-switchers (continued treatment with atorvastatin)
Number of subjects: 5800000
Study 19639351 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient healthcare utilisation
Number of subjects: 5800000
Study 19639351 — intervention group
Group type: EXPERIMENTAL
Intervention: Policy change
Number of subjects: 5800000
Study 17604363 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFN‐alpha‐2b (100 microg weekly) alone or in combination with lamivudine (100 mg daily)
Number of subjects: 70
Study 15166128 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic electrocautery of the ovaries followed by clomiphene citrate and rFSH if anovulation persisted
Number of subjects: 168
Study 15166128 — intervention group
Group type: COMPARATOR
Intervention: Recombinant FSH (rFSH) treatment
Number of subjects: 168
Study 11488938 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (3000 microg retinol equivalent), iron (30 mg), and folate (400 microg)
Number of subjects: 203
Study 11488938 — intervention group
Group type: COMPARATOR
Intervention: Control group (iron (30 mg) and folate (400 microg))
Number of subjects: 203
Study 11488938 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 203
Study 11488938 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 203
Study 10085700 — intervention group
Group type: EXPERIMENTAL
Intervention: Pruritus present in patients
Number of subjects: 51
Study 10085700 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms and signs of neuropathy
Number of subjects: 51
Study 10085700 — intervention group
Group type: EXPERIMENTAL
Intervention: Relationship between pruritus and paresthesia
Number of subjects: 51
Study 8039405 — intervention group
Group type: EXPERIMENTAL
Intervention: Zofenopril calcium (7.5-30 mg twice a day)
Number of subjects: 1500
Study 8039405 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1500
Study 2661184 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipriflavone (Osteofix) 600 mg/day for 6 months
Number of subjects: 20
Study 2661184 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30733029 — intervention group
Group type: EXPERIMENTAL
Intervention: ACL and medial compartment reconstruction surgery (Group 1, n = 58)
Number of subjects: 112
Study 30733029 — intervention group
Group type: COMPARATOR
Intervention: ACL reconstruction and nonsurgical medial compartment treatment (Group 2, n = 54)
Number of subjects: 112
Study 30051927 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete edentulism
Number of subjects: 4524
Study 30051927 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial edentulism
Number of subjects: 4524
Study 30051927 — intervention group
Group type: EXPERIMENTAL
Intervention: Not having dentures
Number of subjects: 4524
Study 30051927 — intervention group
Group type: EXPERIMENTAL
Intervention: Denture disuse
Number of subjects: 4524
Study 30051927 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlates of complete edentulism
Number of subjects: 4524
Study 30051927 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlates of not having dentures and denture disuse
Number of subjects: 4524
Study 30051927 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower than average personal income
Number of subjects: 4524
Study 26977029 — intervention group
Group type: EXPERIMENTAL
Intervention: TIVA (total intravenous anaesthesia) with propofol and remifentanil
Number of subjects: 100
Study 26977029 — intervention group
Group type: COMPARATOR
Intervention: CIIA (combined intravenous and inhaled anaesthesia) with sevoflurane and remifentanil
Number of subjects: 100
Study 24085749 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-community health worker intervention
Number of subjects: 268
Study 24085749 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 268
Study 22328192 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg modified-release metoclopramide tablet every 24 h
Number of subjects: 26
Study 22328192 — intervention group
Group type: COMPARATOR
Intervention: 10 mg immediate-release metoclopramide tablet every 8 h
Number of subjects: 26
Study 22328192 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg modified-release metoclopramide tablet
Number of subjects: 26
Study 22328192 — intervention group
Group type: COMPARATOR
Intervention: 10 mg immediate-release metoclopramide tablet
Number of subjects: 26
Study 19760415 — intervention group
Group type: EXPERIMENTAL
Intervention: I-131 under rhTSH stimulus after 4-day L-T4 withdrawal
Number of subjects: 201
Study 19760415 — intervention group
Group type: EXPERIMENTAL
Intervention: I-131 under rhTSH stimulus after furosemide (25 mg/day for 3 days) and 4-day L-T4 withdrawal
Number of subjects: 201
Study 19760415 — intervention group
Group type: EXPERIMENTAL
Intervention: I-131 under rhTSH stimulus after furosemide (25 mg/day for 3 days) and lithium (450 mg/day for 3 days) following 4-day L-T4 withdrawal
Number of subjects: 201
Study 19760415 — intervention group
Group type: COMPARATOR
Intervention: I-131 30 mCi under rhTSH stimulus without L-T4 withdrawal (control group)
Number of subjects: 201
Study 17430318 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopexamine (Dpx group)
Number of subjects: 16
Study 17430318 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral Nutrition (EN group)
Number of subjects: 16
Study 17430318 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of dopexamine and enteral nutrition
Number of subjects: 16
Study 15769491 — intervention group
Group type: EXPERIMENTAL
Intervention: Subthalamic nucleus deep brain stimulation (STN DBS)
Number of subjects: 30
Study 15769491 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 30
Study 15769491 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative group (PD patients before STN DBS)
Number of subjects: 30
Study 11994327 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Dose (LD) GH replacement therapy (3 microg/kg/day for 3 months, then 6 microg/kg/day for 3 months)
Number of subjects: 595
Study 11994327 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Dose (LD) GH replacement therapy
Number of subjects: 595
Study 11994327 — intervention group
Group type: COMPARATOR
Intervention: Conventional Dose (CD) GH replacement therapy (6 microg/kg/day for 3 months, then 12 microg/kg/day for 3 months)
Number of subjects: 595
Study 11994327 — intervention group
Group type: COMPARATOR
Intervention: Conventional Dose (CD) GH replacement therapy
Number of subjects: 595
Study 11692352 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 2% with noradrenaline 1:50,000 and vasopressin 0.25 IU/mL, and midazolam sedation
Number of subjects: 0
Study 11692352 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam sedation
Number of subjects: 0
Study 7483798 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A - three doses of 20 micrograms i.m. (n = 103)
Number of subjects: 300
Study 7483798 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B - first dose i.d. (2 micrograms), second and third doses i.m. (20 micrograms) (n = 97)
Number of subjects: 300
Study 7483798 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C - first and second doses i.d. (2 micrograms), third dose i.m. (20 micrograms) (n = 100)
Number of subjects: 300
Study 2246786 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive-based smoking cessation program
Number of subjects: 474
Study 2246786 — intervention group
Group type: EXPERIMENTAL
Intervention: Joining the program
Number of subjects: 474
Study 2246786 — intervention group
Group type: EXPERIMENTAL
Intervention: Level of attendance
Number of subjects: 474
Study 6970635 — intervention group
Group type: EXPERIMENTAL
Intervention: Air caloric test (60 s, 12 min, 45 degrees/29 degrees C)
Number of subjects: 20
Study 6970635 — intervention group
Group type: COMPARATOR
Intervention: Water caloric test (30 s, 30 cm3, 44 degrees/30 degrees C)
Number of subjects: 20
Study 31180474 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based intervention
Number of subjects: 391
Study 31180474 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinic-based intervention
Number of subjects: 391
Study 31180474 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 391
Study 29903093 — intervention group
Group type: EXPERIMENTAL
Intervention: BP 200 μmol/L
Number of subjects: 20
Study 29903093 — intervention group
Group type: EXPERIMENTAL
Intervention: BP 400 μmol/L
Number of subjects: 20
Study 29903093 — intervention group
Group type: EXPERIMENTAL
Intervention: BP 800 μmol/L
Number of subjects: 20
Study 25552576 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (40 to 60 minutes, 3 times weekly for 6 months)
Number of subjects: 231
Study 25552576 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group
Number of subjects: 231
Study 25552576 — intervention group
Group type: COMPARATOR
Intervention: Usual-care control group
Number of subjects: 231
Study 24122303 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine
Number of subjects: 0
Study 24122303 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22057944 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone acetate (40 mg, 1 ml)
Number of subjects: 120
Study 22057944 — intervention group
Group type: EXPERIMENTAL
Intervention: Betametazone disodium phosphate (3 mg, 1 ml)
Number of subjects: 120
Study 22057944 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamsinolon acetonate (40 mg, 1 ml)
Number of subjects: 120
Study 22057944 — intervention group
Group type: COMPARATOR
Intervention: Serum physiological (0.09% NaCl, 1 ml)
Number of subjects: 120
Study 19421791 — intervention group
Group type: EXPERIMENTAL
Intervention: Aceclofenac (100 mg) - Tizanidine (2 mg) b.i.d for 7 days
Number of subjects: 197
Study 19421791 — intervention group
Group type: COMPARATOR
Intervention: Aceclofenac (100 mg) alone b.i.d for 7 days
Number of subjects: 197
Study 19421791 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 197
Study 19421791 — intervention group
Group type: EXPERIMENTAL
Intervention: Aceclofenac - Tizanidine
Number of subjects: 197
Study 17466514 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative drainage (n=117)
Number of subjects: 234
Study 17466514 — intervention group
Group type: COMPARATOR
Intervention: No drains (n=117)
Number of subjects: 234
Study 15042359 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening (AFP test and ultrasonography examination every 6 months)
Number of subjects: 18816
Study 15042359 — intervention group
Group type: COMPARATOR
Intervention: Control (no screening)
Number of subjects: 18816
Study 15042359 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening (completed 58.2% of offered screenings)
Number of subjects: 18816
Study 11948037 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation (PR) for 6 to 8 weeks
Number of subjects: 37
Study 9616529 — intervention group
Group type: EXPERIMENTAL
Intervention: salmeterol 50 micrograms b.i.d.
Number of subjects: 426